Viridian Therapeutics Inc.
Organization details
- Legal name
- Viridian Therapeutics Inc.
- Former names
- Miragen Therapeutics, INC. Signal Genetics, INC.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VRDN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001590750
- EIN
- 47-1187261
Board of directors
-
Arlene Morris · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2025
-
Jeffrey Robert Ajer · DirectorSince 2025
-
Jennifer K. Moses · DirectorSince 2023
-
Jonathan Violin · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Sarah Gheuens · DirectorSince 2023
-
Scott Dunseth Myers · Director · Chief Executive OfficerSince 2023
-
Stephen F. Mahoney · Director · President and CEOSince 2023
- Since 2023
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
242% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.3%
-
99.5%
Board connections
7 of this board's directors also sit on 14 other boards. 14 are in the same sector.
-
Cogent Biosciences Inc. Same sectorvia Arlene Morris, Christopher W. Cain and Peter Evan Harwin
-
Crescent Biopharma Inc. Same sectorvia Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
-
Dianthus Therapeutics Inc. Same sectorvia Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
-
Jade Biosciences Inc. Same sectorvia Christopher W. Cain, Peter Evan Harwin and Tomas Kiselak
-
Korsana Biosciences Inc. Same sectorvia Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
-
Damora Therapeutics Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Oruka Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Spyre Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Cartesian Therapeutics Inc. Same sectorvia Scott Dunseth Myers
-
Edgewise Therapeutics Inc. Same sectorvia Arlene Morris
-
Nektar Therapeutics Same sectorvia Jeffrey Robert Ajer
-
Palatin Technologies Inc. Same sectorvia Arlene Morris
-
Zentalis Pharmaceuticals Inc. Same sectorvia Scott Dunseth Myers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $19,999,990
- 1 purchase by 1 insider
- Sold, last 12 months
- $418,990
- 3 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Open-market sale | −4,212 | $24.50 | $103,194 |
| Aug 19, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Option exercise | +10,000 | $14.41 | $144,100 |
| Aug 19, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Open-market sale | −10,000 | $24.50 | $245,000 |
| Aug 14, 2026 | Tripuraneni Radhika Officer (Chief Medical Officer) | Option exercise | +40,000 | $13.21 | $528,400 |
| May 11, 2026 | Fairmount Healthcare Fund II L.P. Director, 10% owner | Open-market purchase | +1,176,470 | $17.00 | $19,999,990 |
| Mar 3, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Option exercise | +5,169 | — | — |
| Mar 3, 2026 | Harmon Seth Officer (Chief Financial Officer) | Option exercise | +6,267 | — | — |
| Mar 3, 2026 | Beetham Thomas W. Officer (Chief Operating Officer) | Option exercise | +9,409 | — | — |
| Mar 3, 2026 | Stephen F. Mahoney Officer (President and CEO) | Option exercise | +18,357 | — | — |
| Mar 3, 2026 | Tousignant Jennifer Officer (Chief Legal Officer) | Shares withheld for tax | −1,724 | $29.32 | $50,548 |
| Mar 3, 2026 | Harmon Seth Officer (Chief Financial Officer) | Shares withheld for tax | −2,091 | $29.32 | $61,308 |
| Mar 3, 2026 | Beetham Thomas W. Officer (Chief Operating Officer) | Shares withheld for tax | −3,138 | $29.32 | $92,006 |
| Mar 3, 2026 | Stephen F. Mahoney Officer (President and CEO) | Shares withheld for tax | −7,627 | $29.32 | $223,624 |
| Dec 31, 2025 | Tousignant Jennifer Officer (Chief Legal Officer) | Open-market sale | −2,272 | $31.16 | $70,796 |
| Oct 23, 2025 | Fairmount Healthcare Fund II GP LLC Director, 10% owner | Open-market purchase | +454,545 | $22.00 | $9,999,990 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Viridian Therapeutics Inc.
Who is the CEO of Viridian Therapeutics Inc.?
Stephen F. Mahoney has been Viridian Therapeutics Inc.'s President and CEO since October 2023.
How many directors are on Viridian Therapeutics Inc.'s board?
Viridian Therapeutics Inc.'s board has 10 directors: Arlene Morris, Christopher W. Cain, Jeffrey Robert Ajer, Jennifer K. Moses, Jonathan Violin, Peter Evan Harwin, Sarah Gheuens, Scott Dunseth Myers, Stephen F. Mahoney and Tomas Kiselak.
Are Viridian Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Viridian Therapeutics Inc. insiders bought $20.0 million of shares in 1 purchase and sold $418,990 of shares in 3 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="viridian-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.